Serous uterine endometrial cancer is a lethal disease for which new therapeutic regimens are urgently needed. Combinations of chemotherapeutic agents and small molecule growth factor inhibitors have demonstrated activity in cancers from other sites. Our objective was to determine whether such a combination using Paclitaxel and Gefitinib could be active in serous endometrial cancer cells.
Paclitaxel, Gefitinib, endometrial cancer, mitotic catastrophe, p38, p53
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.